To sum up, we identified and validated the fact that the inflammatory cytokines IL‐6, IL‐17, VEGF, and IFN‐α might be novel biomarkers for predicting the survival prognosis of patients with HCC and PVTT in triple combination treatment. This evidence concerns the gene IL17A and hepatocellular carcinoma.